Compare AstraZeneca plc (AZN) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs HubSpot Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while HubSpot Inc trades at $210.25 (market cap $11.00B). The key difference: AstraZeneca plc is far larger — about 22.6× HubSpot Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| AZN | HUBS | |
|---|---|---|
Market Cap | $248.14B | $11.00B |
Sector | Health | Technology |
52-Week High | $209.48 | $522.97 |
52-Week Low | $147.06 | $170.39 |
Enterprise Value | $275.41B | $9.89B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
HubSpot (HUBS) trades at $210.12, down 2.68% amid a bearish technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.26 versus $3.02 expected, but lowered its 2026 customer-growth forecast, causing investor concern. Revenue growth remains robust at 20% year-over-year, while profitability metrics show improvement, with net income margin rising to 4.26% in 2025 from negative figures in prior years.
The outlook is mixed: analyst consensus is bullish with a $233.93 price target, but near-term risks include execution challenges in AI adoption and a securities fraud investigation. Long-term growth depends on successful AI product integration and customer acquisition recovery, though competitive and regulatory pressures persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
